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ABSTRACT
Erythropoietin (Epo) is used in clinical settings to enhance hematopoietic function and to improve the quality of life for patients undergoing
chemotherapy by reducing fatigue and the need for transfusions. However, several meta‐analyses have revealed that Epo treatments are
associated with an increased risk of mortality in cancer patients. In this study, we examined the role of Epo in prostate cancer (PCa) progression,
using in vitro cell culture systems and in vivo bone metastatic assays. We found that Epo did not stimulate the proliferation of PCa cell lines, but
did protect PCa cells from apoptosis. In animal models of PCa metastasis, no evidence was found to support the hypothesis that Epo enhances
metastasis. Together, these ﬁndings suggest that Epomay be useful for treating severe anemia in PCa patients without increasingmetastatic risk.
J. Cell. Biochem. 114: 2471–2478, 2013.  2013 Wiley Periodicals, Inc.
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Although high‐dose chemotherapy and radiotherapy prolongsurvival in cancer patients, the side effects of these therapies,
including pancytopenia, remain serious concerns. Pancytopenia, a
condition in which the bone marrow is not able to supply sufﬁcient
numbers of blood cells to the body, occurs due to the cytotoxic effects
of dose‐intensive treatments on rapidly dividing hematopoietic
progenitor cells and slowly dividing hematopoietic stem cells (HSCs).
Under these conditions, external compensation for blood loss is often
required, including red blood cell and platelet transfusions. White
blood cell transfusions, while feasible, are rarely performed, in large
measure due to allergic reactions.
Although a blood transfusion is a simple medical treatment, which
can immediately replace blood loss, it is also a potential source of
infection [Finucane et al., 2000]. Therefore, to minimize the risks to
patients, alternative treatments are often considered. Among the
well‐accepted treatment options for pancytopenia is supportive care
with growth factors and/or cytokines that stimulate blood produc-
tion. Granulocyte colony‐stimulating factor (G‐CSF) has been widely
used to stimulate white blood cell production [Dempke et al., 2000].
Thrombopoietin is involved in platelet production, but is not used for
the treatment of thrombocytopenia despite numerous trials, due to the
frequency of side effects [Dempke et al., 2000]. Erythropoietin (Epo) is
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the primary growth factor known to regulate the production of
erythrocytes [Dempke et al., 2000]. Although Epo improves quality of
life (QoL) in anemic patients, there remains considerable controversy
over the use of Epo for cancer patients as an alternative to blood
transfusion.
In adults, the major source of Epo is the kidney, from which it
travels through the blood stream to the bone marrow to control red
blood cell production. In addition to its enhancement of red blood cell
production, Epo has recently been demonstrated to have protective
effects on non‐erythropoietic tissues (e.g., neuroprotection and
cardioprotection) through its receptor (EpoR) [Arcasoy, 2008]. This
suggests that Epo not only improves hematopoietic conditions, but
also provides other health beneﬁts. Yet several meta‐analyses have
revealed an association between Epo treatment and increased
mortality in cancer patients [Dicato and Plawny, 2010; Hedley
et al., 2011]. Moreover, it has been demonstrated that various cancer
cells express EpoR [Acs et al., 2001; Arcasoy et al., 2003, 2005; Jeong
et al., 2008], and that Epo may promote tumor progression by
stimulating tumor growth [Acs et al., 2001], or angiogenesis
[Ribatti, 2010]. To date, however, little is known regarding the
mechanisms whereby Epo may stimulate tumor progression, the roles
of EpoR in tumor progression, and the relationship between Epo and
metastasis.
Recently, we reported that high dose Epo enhances bone formation
by directly stimulating HSC production of BMPs, and by activating
bone formation by mesenchymal stem cells [Shiozawa et al., 2010].
We also recently demonstrated that prostate cancer (PCa) cells that
disseminate to the bone marrow compete directly with HSCs for
occupancy of the HSC niche [Shiozawa et al., 2011]. We therefore
hypothesized that one mechanism whereby Epo could increase
mortality in cancer patients is by expanding the number of HSC
niches, and therefore increasing the opportunity formetastasis. In this
study we found that Epo did not stimulate the growth of PCa cells in
vitro, nor did Epo enhance PCa bone metastasis in vivo. However, we
did observe that Epo protected PCa cell lines from apoptosis.
Although our ﬁndings reveal that Epo may not directly support PCa
tumor growth and metastasis to bone, there remains a signiﬁcant
need to further understand the biological effects of Epo treatment in
cancer.
MATERIALS AND METHODS
CELL CULTURE
The human PCa cell line PC3 and normal human prostate epithelial
cell line RWPE1 were obtained from the American Type Culture
Collection (Rockville, MD). The human metastatic subline LNCaP C4‐
2B was originally isolated from a lymph node of a patient with
disseminated bony and lymph node involvement [Wu et al., 1998].
PCa cell lines were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA)
with 10% (v/v) fetal bovine serum (FBS; Invitrogen), and 1% (v/v)
penicillin–streptomycin (Invitrogen), and maintained at 37°C, 5%
CO2, and 100% humidity.
RNA EXTRACTION AND REAL‐TIME RT‐PCR
Total RNA was isolated using RNeasy Mini Kit (QIAGEN, Valencia,
CA). First‐strand cDNA was synthesized in a 20ml reaction volume
using 0.4mg of total RNA. RT products were analyzed by real‐time
PCR in TaqMan® Gene Expression Assays for human EpoR and b‐
actin (Applied Biosystems, Foster City, CA). Reactions without
template and/or enzyme were used as negative controls. The PCR
reactions were run for 50 cycles (95°C for 15 s and 60°C for 1min)
after an initial single cycle of 50°C for 2min and 95°C for 10min. The
PCR product was detected as an increase in ﬂuorescence using an ABI
PRISM7,700 instrument (Applied Biosystems). RNA quantity (CR) was
normalized to the housekeeping gene b‐actin by using the formula
CR ¼ 2ð40 Ct of sampleÞ  ð40 Ct of controlÞ. The threshold
cycle (Ct) is the cycle at which a signiﬁcant increase in ﬂuorescence
occurs.
FLOW CYTOMETRY
PCa cell lines and RWPE1 cells were stained with APC anti‐human
monoclonal EpoR antibody (R&D systems, Minneapolis, MN). The
levels of EpoRwere analyzed by a FACSAria dual laserﬂow cytometer
(Becton Dickinson, Franklin Lakes, NJ). In some cases, PCa cells and
RWPE1 cells (80–90% conﬂuent) were cultured in 6‐well plates in
RPMI medium without FBS for 5 h. After serum starvation, the cells
were treated with 20U/ml of Epo (EPOGEN; Amgen, Thousand oaks,
CA) for 30min. The phosphorylation of p44/42 MAP kinase (Thr202/
Tyr204), or Erk1/2, and Akt were analyzed with ﬂow cytometry, using
total Erk1/2 and Akt as internal controls. Antibodies for phosphory-
lated Erk1/2, phosphorylated Akt, total Erk1/2, and total Akt were
purchased from Cell Signaling Technology.
WESTERN BLOT ANALYSES
PCa cells and RWPE1 cells were extracted for protein and analyzed for
EpoR (R&D systems) byWestern blot analysis. b‐actin (Cell Signaling
Technology) was used as an internal control for loading.
SDS–PAGE was performed in 10% polyacrylamide gels. After
electrophoresis, the proteins were transferred to polyvinylidene
diﬂuoride membranes (Bio‐Rad Laboratories, Hercules, CA). The
membranes were then incubated with the primary antibody
overnight, followed by horseradish peroxidase conjugated secondary
antibody (Cell Signaling Technology, Danvers, MA). Proteins were
visualized by autoradiography using an enhanced chemilumines-
cence detection system (Amersham Pharmacia, Piscataway, NJ).
PROLIFERATION ASSAYS
PCa cells were plated into triplicate 96‐well plates at a concentration
of 5,000 cells per well in growth medium with 0.1% FBS. After 24 h,
cells were treated with serial doses of Epo. Thereafter, the cultures
were incubated in an atmosphere of 5% CO2 and 95% O2 at 37°C for
2 days. Proliferation was quantiﬁed using sodium 30‐[1‐[(phenyl-
amino)‐carbonyl]‐3,4‐tetrazolium]‐bis(4‐methoxy‐6‐nitro)benzene‐
sulfonic acid hydrate (XTT) colorimetric assay (Sigma–Aldrich, St.
Louis, MO). Optical intensities were read on a multiwall scanning
spectrophotometer at OD492 (Molecular Devices, Sterling Heights,MI).
APOPTOSIS ASSAYS
PCa cells (80–90% conﬂuent) were cultured in 6‐well plates in RPMI
medium without FBS for 5 h. After serum starvation, the cells were
treated with 5 U/ml of Epo for 24 h. The cells were stained for
apoptosis using annexin V PE (BD Biosciences, San Jose, CA) and
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7AAD (BD Biosciences), according to the manufacturer0s protocol,
and apoptotic cells were quantiﬁed by ﬂow cytometry.
IMMUNOHISTOCHEMISTRY
Murine bones were harvested, ﬁxed in 10% buffered formalin,
decalciﬁed in 10% EDTA, and embedded in parafﬁn, and 5–7mm
sections were prepared. Masson0s trichrome staining (Sigma–Aldrich)
was done, and measurements were made of numbers of osteoblasts
per millimeter of bone surface using NIS elements (Nikon Instruments
Inc., Melville, NY) imaging software. For each condition, slides were
counted in eight ﬁelds. In some case, murine bones were stained with
antibodies to SDF‐1 (Abcam, Cambridge, MA: pre‐stained with
Zenon® Alexa Fluor® 488 rabbit IgG1 labeling kit; Invitrogen).
Confocal laser scanning was performed with a FV500 microscope
(Olympus, Center Valley, PA).
IN VIVO METASTASIS ASSAYS
Luciferase‐expressing PC3 (PC3Luc) cells were introduced into male
SCID mice by intracardiac injections. For 4 weeks prior to or post
tumor inoculation, the recipient mice were treated by intraperitoneal
injections with Epo (6,000U/kg/day, three times per week) or vehicle.
Bone metastatic regions were measured by bioluminescence imaging.
Total tumor burden of each animal was calculated using regions of
interest (ROI) that encompassed the entire animal.
COL2.3D‐TK ANIMALS AND TREATMENTS
Transgenic mice bearing a fusion gene composed of the 2.3‐kb
fragment of the rat type I collagen a1 (Col1a1) promoter and HSV‐TK
(Col2.3D‐TK) [Visnjic et al., 2001] were graciously provided by Dr.
David W. Rowe (University of Connecticut, Farmington, CT). Four‐ to
6‐week‐old mice bearing the Col2.3DTK transgene and age‐matched
control CD‐1 mice were intraperitoneally injected with ganciclovir
(Cytovene‐IV; Roche, Nutley, NJ; 3–8mg/kg per day), or vehicle
(0.9% saline) for 3 weeks with/without PTH (hPTH134; Bachem,
Torrence, CA; 50–80mg/kg per day), or Epo (6,000U/kg/day, three
times per week) injections.
BONE MARROW TRANSPLANTATION ASSAYS
Prior to bone marrow transplantation, mice were treated with PTH or
Epo to expand the bone marrow niche. Recipient mice were exposed
twice to 570 cGy given 3 h apart in a gamma cell 40 cesium source.
One hour later the mice were injected intravenously with a mixture of
a radioprotective dose of CD45.2 cells (2 105 cells) and CD45.1
donor cells in 100ml. Starting at 4 weeks after transplantation and
continuing for at least 16 weeks, the CD45.1 phenotypes were
measured in peripheral blood.
STATISTICAL ANALYSES
All in vitro experiments were performed at least three times with
similar results. Results from representative assays are shown.
Numerical data are expressed as mean SEM. Statistical analysis
was performed by ANOVA or unpaired two‐tailed Student0s t‐test
using GraphPad Instat (GraphPad). For QPCR assays, Kruskal–Wallis
test and Dunn multiple‐comparisons test was used. For all analyses, a
P value <0.05 was considered signiﬁcant.
RESULTS
EPO DOES NOT STIMULATE PROLIFERATION OF PCA CELLS
In many systems, the binding of Epo to its receptor is believed to
regulate a variety of cellular responses, including cell proliferation
and cell survival. Therefore, we evaluated the effects of Epo on PCa
cells in these fundamental cellular functions. To explore the
interaction of exogenous Epo treatment and EpoR expression in
PCa cells, we ﬁrst examined the basal mRNA expression levels of the
EpoR in PCa cells by QRT‐PCR. A higher level expression of EpoR was
observed in PCa cells, compared to the normal prostate epithelial cell
line RWPE1 cells (Fig. 1A). To further evaluate if EpoR mRNA
Fig. 1. PCa cells express EpoR. (A) EpoR mRNA levels of PCa cell lines (PC3 and
C4‐2B) and RWPE1 cells were determined by real time RT‐PCR. Data were
normalized to b‐actin and are presented as mean SEM from three
independent PCRs. Representative (B) ﬂow cytometric analyses and
(C) Western blotting of EpoR on PCa cells.
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expression is correlated with protein levels, cell surface EpoR
expression was analyzed by ﬂow cytometry using commercially
available anti‐EpoR antibodies. Although the expression of EpoR is
extremely low in all cell types, the level of expression of EpoR protein
by PCa cells was detected and was higher than that seen in RWPE1
cells (Fig. 1B). These observations were further conﬁrmed by Western
blotting (Fig. 1C).
To determine if EpoR expressed on PCa cells is activated in
response to Epo treatment, phosphorylation of Erk1/2 and Akt in
treated PCa and RWPE1 cells were evaluated by ﬂow cytometry. The
data demonstrated that Epo induces phosphorylation of Erk1/2 in
both PC3 and C4‐2B cells, while it had no effect on RWPE1 cells (Fig.
2A). A similar trend was observed in the phosphorylation of Akt (Fig.
2B). These data suggest that activation of PCa cells by Epo through
EpoR is possible.
To determine whether Epo regulates proliferation of PCa cells
through EpoR, in vitro XTT assays were performed. After 2 days of
culture with and without varying concentrations of Epo, we observed
no effect on proliferation of the PCa cells (Fig. 2C,D).
EPO PROTECTS PCA CELLS FROM APOPTOSIS
To determine if Epo can regulate PCa survival, apoptosis initiated by
serum starvation in the presence or absence of Epo was evaluated by
ﬂow cytometry using annexin V staining methods. The data
demonstrate that signiﬁcantly fewer apoptotic cells were detected
in Epo‐treated cells than controls (Fig. 3A).
The maintenance and protection from apoptosis and injury of
HSCs in the marrow is predominantly a function of the HSC
endosteal niche, a region largely populated by osteoblasts [Shiozawa
and Taichman, 2012]. Recently, we demonstrated that PCa cells
target this region in marrow to establish metastatic footholds, and
that the niche protects PCa cells from apoptosis [Shiozawa
et al., 2011]. To address whether the protective role of Epo is
dependent on the osteoblastic niche, we used a genetically
engineered animal model, in which thymidine kinase is placed
under control of the collagen I promoter (hereinafter referred to as
Col2.3D‐TK animals). In this animal model ganciclovir treatment
conditionally ablates osteoblasts in the marrow [Visnjic et al., 2004].
In this experiment, parathyroid hormone (PTH) was used as a control,
since it has also been shown to expand osteoblastic niches [Calvi
et al., 2003]. Without ganciclovir, there were no differences in the
number of hematopoietic cells in the marrow between vehicle, PTH,
and Epo treatment in this animal model (Fig. 3B). In contrast, the
number of osteoblasts in PTH and Epo treated animals were increased
(Fig. 3C). Ganciclovir alone had no effect on the number of
hematopoietic cells in the marrow of control animals (Fig. 3B), but
dramatically decreased the number of osteoblasts in Col2.3D‐TK
animals regardless of treatment (Fig. 3C). Interestingly, Epo
treatment prevented the cells from undergoing apoptosis initiated
by the ablation of osteoblastic niche, whereas neither vehicle nor
PTH treatment protected the marrow cells from apoptosis (Fig. 3B).
Therefore, although this experiment was performed in the
Fig. 2. Epo activate MAPK pathway in PCa cells, but does not stimulate proliferation. (A, B) PCa cell lines (PC3 and C4‐2B) and RWPE1 cells were cultured in medium without FBS
for 5 h. After serum starvation, the cells were treated with 20 U/ml of Epo for 30min, and phosphorylation of (A) Erk1/2 and (B) Akt were analyzed by ﬂow cytometry at 0, 10, and
30min. Total Erk1/2 and Akt were used as internal controls, respectively. Data are presented as mean SEM from triplicate determinations. P< 0.05 and #P< 0.01 versus 0min in
the titration period. (C) PC3 cells and (D) C4‐2B cells were seeded at 5,000 cells per well in 96‐well plates and cultured with 0.1% FBS in the presence or absence of Epo (0–5U/ml).
After 48 h, cell proliferation was assessed using the XTT assay. Data are presented as mean SEM from triplicate determinations. N.S. indicates not signiﬁcant.
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hematopoietic system, the data suggest that Epo protects cells from
apoptosis, but in a niche‐independent manner.
EPO DOES NOT DIRECTLY REGULATE BONE METASTASIS OF PCA
CELLS
To explore if Epo is critical for the development of bone metastases in
vivo, luciferase‐expressing PC3 cells (PC3Luc cells) were inoculated
into SCID mice by intracardiac injection. The animals were treated
either with vehicle, Epo prior to tumor inoculation, or Epo post tumor
inoculation. Development of bone metastases was followed over time
using bioluminescence imaging. Surprisingly, neither pre‐treatment
with Epo nor treatment after tumor inoculation altered the
development of bone metastases (Fig. 4A).
Recently, we demonstrated that pre‐treatment of animals with
anabolic dosing of PTH increased bone metastasis from PCa cells by
expanding the bone marrow niche size [Shiozawa et al., 2011]. Based
upon the fact that the Epo has a protective effect on the cells in the
marrow (Fig. 3B), we hypothesized that the occupancy of the marrow
space by the cells protected by Epo would prevent the cell trafﬁcking
process to the marrow, even if Epo also expands the size of niche. To
test this hypothesis, two sets of studies were performed. First, bone
marrow transplantation assays with/without Epo treatment were
performed, since the homing process of HSCs well represents the cell
Fig. 3. Epo protects PCa cells from apoptosis. (A) PC3 cells were treatedwith Epo (5 U/ml) in serum‐free medium for 24 h. The effect of Epo on apoptosis of PCa cells was measured
by ﬂow cytometry using annexin V staining. Data are presented as mean SEM from triplicate determinations. #P< 0.01 versus vehicle treatment. B, C: Col2.3D‐TK mice were
treated with either ganciclovir to ablate the osteoblast niche or vehicle, with/without PTH or Epo for 3 weeks. (B) Representative Masson0s trichrome staining of long bones. Original
magniﬁcation, 40. Scale bars: 50mm. (C) Osteoblast number was quantiﬁed with Masson0s trichrome staining. Data are presented as mean SEM. #P< 0.01 versus vehicle
treatment.
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trafﬁcking process to the marrow. As a control for the niche
expansion, mice were also treatedwith PTH. There were no signiﬁcant
differences between treatments when analyzing % engraftment of
transfused cells to the marrow of recipient mice (Fig. 4B). As before,
although this experiment was performed in the hematopoietic system,
the data suggest that the cell trafﬁcking to the marrow may not be
directly correlated to niche numbers.
At the molecular level, it has been well accepted that SDF‐1
secreted by the bone marrow microenvironment plays an important
role in bone metastasis, including PCa [Muller et al., 2001; Taichman
et al., 2002]. Therefore, we hypothesized that SDF‐1 expression in
marrow is responsible for the differences in the metastatic potential
between PTH‐ and Epo‐treated mice, and thus SDF‐1 levels in the
marrow were evaluated by immunohistochemistry. As expected,
PTH‐treated mice express more SDF‐1 in the marrow, compared to
vehicle‐treated mice (Fig. 4C). Surprisingly, lower levels of SDF‐1
expression were observed in the bone marrow of Epo‐treated mice,
compared to PTH‐treatments (Fig. 4C).
DISCUSSION
In this study, we examined the role of Epo in PCa tumor progression
using in vitro cell culture models and in vivo metastatic assays. We
found that Epo does not enhance the proliferation of PCa cell lines in
vitro, however, it does prevent cells from undergoing apoptosis when
stressed by serum starvation. More importantly, we observed that Epo
does not affect the metastatic cascade of PCa cells in an in vivo model
of metastasis. Together, our data suggest that promotion of PCa
metastasis or induction of proliferation by PCa cells are unlikely to be
the cause of enhanced mortality following Epo therapy in PCa.
While the biological roles of Epo in erythropoiesis and tissue
protection has been revealed [Arcasoy, 2008], the use of Epo for
treatment of anemia in cancer patients is still controversial. Recent
clinical studies have suggested that Epo adversely affects the
prognosis in cancer patients. It has been suggested that Epo promotes
tumor growth through EpoR, and that Epo activates several signaling
pathways (Jak2/Stat3, PI3K/AKT, MAPK) [Hedley et al., 2011].
Indeed, some in vitro studies have demonstrated that Epo enhances
tumor proliferation [Westenfelder and Baranowski, 2000; Acs
et al., 2001; Yasuda et al., 2003; Feldman et al., 2006]. However,
others have demonstrated that no effects of Epo on tumor growth
were observed in vitro [Dunlop et al., 2006; Jeong et al., 2008], and in
vivo [Kataoka et al., 2010]. Our current study failed to reveal any
stimulatory effects of Epo on tumor growth, however, we did ﬁnd that
Epo inhibits PCa cell apoptosis. As most assays to determine cell
proliferation measure the number of viable cells, data obtained from
these assays do not always correlate with cell proliferation. Therefore,
an alternative explanation for the differences seen in various studies
may be in the nature of the assays themselves. Consistent with these
ﬁndings, it has been demonstrated that Epo protects tumor cells from
cytotoxic insults through EpoR [Brines et al., 2004; Arcasoy, 2008].
Fig. 4. Epo does not alter bonemetastasis of PCa cells. (A) Luciferase‐expressing PCa cells were injected systemically by intracardiac injection into SCID mice. Either prior to or post
tumor inoculation, micewere treatedwith Epo.Metastatic regions weremeasured by a bioluminescence imaging. Bioluminescence images are presented as the relative photon counts
of each individual (n¼ 10). Data are presented as the mean SEM. N.S. indicates not signiﬁcant. (B) Competitive long‐term bone marrow transplantations were used to determine
the effect of the occupancy of the marrow space on cell trafﬁcking to the bone marrow. Bone marrow cells derived from CD45.1 mice (2 105 cells) were transplanted into CD45.2
congenic C57BL6 mice along with a mixture of a radioprotective dose of CD45.2 cells (2 105 cells). Epo or PTH was used to expand the osteoblastic niche prior to irradiation. The
percentages of engraftment of CD45.1 cells were determined in peripheral blood analyzed byﬂow cytometry over time (n¼ 10). Data are presented as themean SEM. N.S. indicates
not signiﬁcant. (C) Representative SDF‐1 immunostaining of long bones. Arrows indicate the region of SDF‐1‐positive. Original magniﬁcation, 60. Scale bars: 25mm.
2476 ERYTHROPOIETIN AND PROSTATE CANCER JOURNAL OF CELLULAR BIOCHEMISTRY
Previous in vitro studies may have interpreted the cell protective role
of Epo as cell proliferation rather than a decrease in apoptosis.
Epo is believed to activate a signal transduction cascade in cancer
cells through its receptor on their surface. However, the roles of Epo in
non‐hematopoietic tissues, including cancer cells, remain conﬂicting.
EpoR mRNA expression has been detected in several tumors and
cancer cell lines [Acs et al., 2001; Arcasoy et al., 2003; Arcasoy
et al., 2005; Jeong et al., 2008]. Although EpoR protein was detected
by ﬂow cytometry and Western blotting in this study, there remains
debate as to whether commercially available antibodies for EpoR are
adequately speciﬁc and EpoR, a membrane receptor, is often detected
in cytoplasm [Jelkmann and Laugsch, 2007]. Moreover, Epomay bind
to diverse receptors to activate cancer cells, since EpoR exist as a
multi‐receptor complex with a b common receptor [Jubinsky
et al., 1997; Brines et al., 2004]. As a result, the direct interaction
between Epo and EpoR in cancer cells is not yet fully understood.
Conversely, Epo may affect tumor progression indirectly by
stimulating angiogenesis [Ribatti, 2010]. For example, studies have
demonstrated that anti‐angiogenic therapy reduces tumor sizes
[Ingber et al., 1990; O0Reilly et al., 1994, 1997; Folkman, 1995],
suggesting that vasculature surrounding tumor cells supports tumor
growth. It has also been reported that Epo enhances angiogenesis by
mobilizing endothelial progenitor cells (EPCs) from bone marrow
[Heeschen et al., 2003; Bahlmann et al., 2004]. However, the
contribution of either Epo itself or to EPC‐induced tumor vasculari-
zation has not yet been observed in an in vivo setting [Jelkmann and
Elliott, 2012]. In addition to these observations, endothelial cells in
other non‐hematopoietic tissue may also express Epo mRNA and
functional EpoR, yet these results remain contentious [Sinclair
et al., 2010]. Collectively, while the subject of Epo production outside
of the kidney and EpoR expression remains in debate, the effects of
Epo on tumor progression may be substantially limited. Clearly,
further studies are needed.
Epo has been thought to improve QoL in the patients undergoing
chemotherapy by reducing fatigue and the need for blood transfusions.
Recent clinical trials testing the prophylactic effects of Epo on
chemotherapy‐induced anemia were terminated early, since Epo
increased mortality in cancer patients [Leyland‐Jones, 2003; Wright
et al., 2007]. It was initially speculated this is due mainly to tumor
growth initiated by Epo. However, growing evidence suggests that Epo
may initiate thrombosis, resulting in a higher mortality [Fandrey and
Dicato, 2009], although detailed mechanisms are still unknown. One
potential means behind this may be due to hyperviscosity caused by
increased red blood cell production and reduction of plasma volume
[Spivak et al., 2009]. Epo is also believed to enhance platelet levels by
stimulating the production or release of other inﬂammatory cytokines
[Spivak et al., 2009]. Often in cancer patients, hypercoagulation and
enhancedplatelet aggregationareobserved. Importantly, recent studies
suggest that platelets play a crucial role in tumor progression and
metastasis [Gay and Felding‐Habermann, 2011]. Platelets are believed
to promote the migration/invasion of tumor cells, maintain their
survival in the blood stream, protect them from immunosurveillance,
andsupport theestablishmentofmetastases insecondarysites [Gayand
Felding‐Habermann, 2011]. Nevertheless, many of these postulated
events in tumor progression were not mimicked in our model of bone
metastasis. Therefore, a direct effect of Epo on tumor progression may
be possible, or Epo may inﬂuence the metastatic cascade in different
ways than were examined in our study.
Little is known regarding the impact of Epo on the metastatic
process, although this drug may have profound effects on local tumor
progression. It has been demonstrated that primary solid tumors
spread to the marrow utilizing similar mechanisms as HSC homing
[Muller et al., 2001; Taichman et al., 2002]. We have recently
demonstrated that disseminated PCa cells travel to the HSC niche and
then take up the residence in the niche to eventually form ametastasis
[Shiozawa et al., 2011]. These ﬁndings suggest that the HSC niche
plays an essential role in the development of metastasis. As seen with
PTH (12), we recently reported that Epo expands the HSC niche in the
marrow by either directly driving the differentiation of mesenchymal
stem cells or indirectly through BMP signaling by HSCs [Shiozawa
et al., 2010]. In our current study, Epo did not increase bone
metastasis of PCa, despite a resultant increase in the niche with
treatment in this transgenic animal model. A potential reason for this
discrepancy may be the SDF‐1 response in the bone marrow to Epo
and PTH. SDF‐1 is a ligand for the chemokine receptors CXCR4 and
CXCR7 [Sun et al., 2010]. The one ofmajor roles of SDF‐1 is to serve as
a chemoattractant for CXCR4/7 expressing tumor cells and HSCs [Sun
et al., 2010]. We found that PTH treatment stimulates the secretion of
SDF‐1 in the marrow, however, we observed here that when animals
were treated with Epo, SDF‐1 levels in the marrow were suppressed.
These data suggest that Epo affects the HSC niche differently from
PTH, and as a result these two hormones may have opposite effects on
bone metastasis, even though they both expand the niche size.
Excluding venous thrombosis, adverse effects of Epo treatment for
cancer patients are still largely controversial. Despite concerns about
the mortality risk, Epo is, however, still a viable treatment option for
cancer patients with anemia, as it could potentially improve their QoL
and reduce the need for transfusions. Therefore, further well‐
designed, controlled clinical trials in this area are clearly warranted in
order to ensure the safe use of Epo for treatment of anemia in cancer
patients. Ultimately, whether prophylactic Epo treatment is appro-
priate should be decided on a case‐by‐case basis until the existence of
functional EpoR, the impacts of EpoR on the prognosis, and the roles
of Epo/EpoR in tumor progression are biologically determined.
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